

Siemens Healthineers is developing a leading POC product for the rapid detection of acute SARS-COV2 (COVID-19) infection



Product



Point Of Care RAPID COVID-19 Antigen test

Sample types:

- Nasal Swab
- Throat Swab
- Saliva

Time to result = 15-20 mins

Easy to use visual read; no instrument required

Availability



Expected CE mark date

On or before October 13, 2020



Manufacturing capacity

Up to 38 million tests per month


Specifications

- Double antibody based, lateral flow chromatographic immunoassay
- Qualitative detection of the SARS-COV2 virus antigen in various sample types include nasal and throat swabs
- No cross-reactivity detected with MERS, 4 common coronaviruses, Flu A or Flu B
- Expected sensitivity and specificity: On par or better than existing approved Antigen tests in market
 - Targeted sensitivity > 96.5%
 - Targeted specificity > 99.5%
- Intended for professional use only
- Future iterations may include pharmacy and/or home use

Target audiences for wide-scale testing




SIEMENS
Healthineers



SARS-COV-2 Infektion

Einordnung von Antigen in den Krankheitsverlauf



CATCHING COVID-19

Different types of COVID-19 test can detect the presence of the SARS-CoV-2 virus or the body's response to infection. The probability of a positive result varies with each test before and after symptoms appear.

- PCR-based tests** can detect small amounts of viral genetic material, so a test can be positive long after a person stops being infectious.
- Rapid antigen tests** detect the presence of viral proteins and can return positive results when a person is most infectious.
- Antibody tests** detect the body's immune response to the virus and are not effective at the earliest phase of infection.

Exposure to virus Symptom onset

Der Einsatz des SARS-COV-2 Antigen Tests unterstützt die Eindämmung und verhindert die Ausbreitung von COVID-19

